Akira Shimada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4289085/publications.pdf

Version: 2024-02-01

686830 344852 1,383 45 13 36 citations h-index g-index papers 46 46 46 1525 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Acute kidney injury in Japanese type 2 diabetes patients receiving sodium–glucose cotransporter 2 inhibitors: A nationwide cohort study. Journal of Diabetes Investigation, 2022, 13, 42-46.	1.1	5
2	Japanese Type 1 Diabetes Database Study (TIDE-J): rationale and study design. Diabetology International, 2022, 13, 288-294.	0.7	4
3	Current clinical state of type 1 diabetes in Saitama prefecture. Diabetology International, 2022, 13 , 436-446.	0.7	2
4	Combination of anti D25 antibody and poly I:C treatment in pregnant NOD mice may be used as "pregnancyâ€related―type 1 diabetes model. Journal of Diabetes Investigation, 2022, , .	1.1	0
5	Onâ€label use of sodium–glucose cotransporterÂ2 inhibitors might increase the risk of diabetic ketoacidosis in patients with typeÂ1 diabetes. Journal of Diabetes Investigation, 2021, 12, 1586-1593.	1.1	8
6	Differences in the birthweight of infants born to patients with early- or mid-to-late-detected gestational diabetes mellitus who underwent guideline-based glycemic control. Journal of Diabetes and Its Complications, 2021, 35, 107850.	1.2	5
7	Characteristics Associated with Early Worsening of Retinopathy in Patients with Type 2 Diabetes Diagnosed with Retinopathy at Their First Visit: A Retrospective Observational Study. Journal of Diabetes Research, 2021, 2021, 1-9.	1.0	1
8	Neurofibromatosis Type 1 with Concurrent Multiple Endocrine Disorders: Adenomatous Goiter, Primary Hyperparathyroidism, and Acromegaly. Internal Medicine, 2021, 60, 2451-2459.	0.3	1
9	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Research and Care, 2021, 9, e001787.	1.2	15
10	Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-NaÃ-ve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial. Diabetes Therapy, 2021, 12, 3201-3215.	1.2	7
11	Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial. Journal of Clinical Medicine Research, 2021, 13, 502-509.	0.6	2
12	HbA1c level may be a risk factor for oxygen therapy requirement in patients with coronavirus disease 2019. Journal of Diabetes Investigation, 2021, , .	1.1	4
13	Clinical Significance of Insulin Peptide–specific Interferon-γ–related Immune Responses in Ketosis-prone Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	2
14	Bodyweight threshold for sudden onset of ketosis might exist in ketosisâ€prone typeÂ2 diabetes patients. Journal of Diabetes Investigation, 2020, 11, 499-501.	1.1	3
15	Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study. BMJ Open Diabetes Research and Care, 2020, 8, e001856.	1.2	18
16	Fulminant type 1 diabetes: nationwide effort to elucidate genetics, etiology, and pathogenesis since 2000. Diabetology International, 2020, 11 , $342-343$.	0.7	0
17	Twenty years since the discovery of fulminant type 1 diabetes. Diabetology International, 2020, 11 , 309-309.	0.7	1
18	Clinical characterization of patients with primary aldosteronism plus subclinical Cushing's syndrome. BMC Endocrine Disorders, 2020, 20, 9.	0.9	9

#	Article	IF	CITATIONS
19	A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab. Case Reports in Hematology, 2020, 2020, 1-4.	0.3	1
20	Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants in <i>CSAD/Inc-ITGB7-1</i> on Chromosome 12q13.13 Associated With Susceptibility to Fulminant Type 1 Diabetes. Diabetes, 2019, 68, 665-675.	0.3	31
21	Weight control before and during pregnancy for patients with gestational diabetes mellitus. Journal of Diabetes Investigation, 2019, 10, 1075-1082.	1.1	14
22	Characteristics of Gut Microbiota in Patients With Diabetes Determined by Data Mining Analysis of Terminal Restriction Fragment Length Polymorphisms. Journal of Clinical Medicine Research, 2019, 11, 401-406.	0.6	2
23	Intrinsic insulin secretion capacity might be preserved by discontinuing antiâ€programmed cell death protein 1 antibody treatment in †antiâ€programmed cell death protein 1 antibodyâ€induced' fulminant type diabetes. Journal of Diabetes Investigation, 2018, 9, 448-449.	e 1 .1	11
24	Diffusion-weighted magnetic resonance imaging in the pancreas of fulminant type 1 diabetes. Diabetology International, 2018, 9, 257-265.	0.7	2
25	Distinct Inflammatory Changes of the Pancreas of Slowly Progressive Insulin-dependent (Type 1) Diabetes. Pancreas, 2018, 47, 1101-1109.	0.5	12
26	Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4â€week, doubleâ€blind, randomized, placeboâ€controlled phase 2 trial. Diabetes, Obesity and Metabolism, 2018, 20, 2190-2199.	2.2	34
27	The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. Npj Aging and Mechanisms of Disease, 2018, 4, 7.	4.5	35
28	Administration of thiamazole for Graves' disease might trigger the onset of type 1 diabetes. Journal of Diabetes Investigation, 2018, 9, 1228-1229.	1.1	2
29	Evaluation of Teneligliptin Effects on Transcriptional Activity of PPARγ in Cell-Based Assays. Journal of Nippon Medical School, 2018, 85, 95-101.	0.3	O
30	Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study. Journal of Clinical Medicine Research, 2018, 10, 679-687.	0.6	7
31	Case of type 1 diabetes associated with lessâ€dose nivolumab therapy in a melanoma patient. Journal of Dermatology, 2017, 44, 605-606.	0.6	43
32	Factors affecting consultation length in a Japanese diabetes practice. Diabetes Research and Clinical Practice, 2017, 126, 54-59.	1.1	12
33	Effects of the Activation of Three Major Hepatic Akt Substrates on Glucose Metabolism in Male Mice. Endocrinology, 2017, 158, 2659-2671.	1.4	8
34	Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care, 2017, 40, 1364-1372.	4.3	216
35	Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study. Journal of Clinical Medicine Research, 2017, 9, 154-162.	0.6	11
36	Autoimmunity as an etiology of fulminant type 1 diabetes. Diabetology International, 2016, 7, 104-105.	0.7	0

#	Article	IF	CITATIONS
37	Pancreatic ductal hyperplasia/dysplasia with obstructive chronic pancreatitis: an association with reduced pancreatic weight in type 1 diabetes. Diabetologia, 2016, 59, 865-867.	2.9	10
38	Diagnostic criteria for acuteâ€onset type 1 diabetes mellitus (2012): Report of the <scp>C</scp> ommittee of <scp>J</scp> apan <scp>D</scp> iabetes <scp>S</scp> ociety on the <scp>R</scp> esearch of <scp>F</scp> ulminant and <scp>A</scp> cuteâ€ <scp>o</scp> nset <scp>T</scp> ype 1 <scp>D</scp> iabetes <scp>M</scp> ellitus, Journal of Diabetes Investigation, 2014, 5, 115-118.	1.1	82
39	Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acuteâ€onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). Journal of Diabetes Investigation, 2012, 3, 536-539.	1.1	187
40	A Mimic of Viral Double-Stranded RNA Triggers Fulminant Type 1 Diabetes-like Syndrome in Regulatory T Cell-Deficient Autoimmune Diabetic Mouse. Journal of Immunology, 2011, 187, 4947-4953.	0.4	12
41	Enterovirus Infection, CXC Chemokine Ligand 10 (CXCL10), and CXCR3 Circuit. Diabetes, 2009, 58, 2285-2291.	0.3	148
42	Fulminant Type 1 Diabetes: A nationwide survey in Japan. Diabetes Care, 2003, 26, 2345-2352.	4.3	278
43	Systemic Administration of IL-18 Promotes Diabetes Development in Young Nonobese Diabetic Mice. Journal of Immunology, 2003, 171, 5865-5875.	0.4	74
44	A Case of Fulminant Type 1 Diabetes With Strong Evidence of Autoimmunity. Diabetes Care, 2002, 25, 1482-1483.	4.3	26
45	T-Cell-Mediated Autoimmunity May Be Involved in Fulminant Type 1 Diabetes. Diabetes Care, 2002, 25, 635-636.	4.3	38